Publications dans lesquelles il/elle collabore avec Miguel Ángel Climent Durán (23)

2024

  1. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538

  2. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  3. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  4. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441

  5. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

  2. Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502

  3. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

    Critical Reviews in Oncology/Hematology, Vol. 174

2020

  1. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

  2. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

  3. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

    International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444

2019

  1. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  3. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

    Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226

2016

  1. Controversies in the treatment of metastatic kidney cancer: A case report and review of the literature

    Cancer and Chemotherapy Reviews, Vol. 11, Núm. 1, pp. 3-11

  2. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02

    Annals of Oncology, Vol. 27, pp. vi277

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

2014

  1. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1